---
figid: PMC9255545__41577_2022_746_Fig1_HTML
figtitle: Drug targets in the IL-23–IL-17 pathway
organisms:
- Escherichia coli
- Staphylococcus aureus
- Mycobacterium tuberculosis
- Pseudomonas aeruginosa
- Helicobacter pylori
- Salmonella enterica subsp. enterica serovar Typhimurium
- Listeria monocytogenes
- Streptococcus pneumoniae
- Klebsiella pneumoniae
- Haemophilus influenzae
- Bacteroides fragilis
- Borreliella burgdorferi
- Citrobacter rodentium
- Francisella tularensis
- Cutibacterium acnes
- Candidatus Arthromitus sp. SFB-mouse
- Helicobacter hepaticus
- Bordetella pertussis
- Moraxella catarrhalis
- segmented filamentous bacterium
- Cutibacterium acnes 17B
- Human immunodeficiency virus 1
- Severe acute respiratory syndrome coronavirus 2
- Human alphaherpesvirus 1
- unidentified influenza virus
- Respiratory syncytial virus
- H1N1 subtype
- Human T-cell leukemia virus type I
- Human alphaherpesvirus 2
- Coxsackievirus B3
- Saimiriine gammaherpesvirus 2
- enterovirus D68
- Trypanosoma cruzi
- Toxoplasma gondii
- Leishmania major
- Leishmania donovani
- Schistosoma mansoni
- Leishmania infantum
- Fasciola hepatica
- Schistosoma japonicum
- Nippostrongylus brasiliensis
- Heligmosomoides polygyrus
- Candida albicans
- Paracoccidioides brasiliensis
- Carex albicans var. albicans
- Cryptococcus neoformans var. neoformans
- Microsporum canis
- Homo sapiens
- Macaca mulatta
- Mus musculus
- NA
pmcid: PMC9255545
filename: 41577_2022_746_Fig1_HTML.jpg
figlink: /pmc/articles/PMC9255545/figure/Fig1/
number: F1
caption: Activation of dendritic cells (DCs) and macrophages through pathogen recognition
  receptors (PRRs) promotes production of IL-23 and IL-1β, which play a major role
  in the induction and/or expansion of populations of T helper 17 (TH17) cells, IL-17-secreting
  γδ T (γδT17) cells and other IL-17-secreting cells (not shown). By contrast IL-12
  production by DCs and macrophages promotes development of TH1 cells. Monoclonal
  antibodies (mAbs) that neutralize IL-12p40 (ustekinumab) suppress TH1 cell as well
  as TH17 cell and γδT17 cell responses, whereas mAbs that neutralize IL-23 (guselkumab,
  tildrakizumab and risankizumab) specifically block IL-17-secreting cells. The RORγt
  transcriptional factor is the master regulator of IL-17 production in diverse cell
  types and a target for small molecule drugs (SMDs) in development. TH17 cells, γδT17
  cells and other IL-17-secreting cells (not shown) co-produce IL-17A and IL-17F and,
  while most of the focus has been on mAbs specific for IL-17A (secukinumab and ixekizumab),
  antibodies that neutralize both IL-17A and IL-17F (bimekizumab) are also in clinical
  use. These, together with mAbs that bind to IL-17RA (brodalumab) and inhibit binding
  of IL-17A and IL-17F to IL-17RA–IL-17RC, appear to be marginally more effective
  than anti-IL-17A mAbs. Finally, peptides, macrocycles and other SMDs that target
  IL-17R or ACT1 are also in development. GM-CSF, granulocyte–macrophage colony-stimulating
  factor; PAMP, pathogen-associated molecular pattern.
papertitle: IL-17 and IL-17-producing cells in protection versus pathology.
reftext: Kingston H. G. Mills. Nat Rev Immunol. 2023;23(1):38-54.
year: '2023'
doi: 10.1038/s41577-022-00746-9
journal_title: Nature Reviews. Immunology
journal_nlm_ta: Nat Rev Immunol
publisher_name: Nature Publishing Group UK
keywords: Immunotherapy | Cytokines | Antimicrobial responses
automl_pathway: 0.935789
figid_alias: PMC9255545__F1
figtype: Figure
organisms_ner:
- Macaca mulatta
- Homo sapiens
- Mus musculus
redirect_from: /figures/PMC9255545__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9255545__41577_2022_746_Fig1_HTML.html
  '@type': Dataset
  description: Activation of dendritic cells (DCs) and macrophages through pathogen
    recognition receptors (PRRs) promotes production of IL-23 and IL-1β, which play
    a major role in the induction and/or expansion of populations of T helper 17 (TH17)
    cells, IL-17-secreting γδ T (γδT17) cells and other IL-17-secreting cells (not
    shown). By contrast IL-12 production by DCs and macrophages promotes development
    of TH1 cells. Monoclonal antibodies (mAbs) that neutralize IL-12p40 (ustekinumab)
    suppress TH1 cell as well as TH17 cell and γδT17 cell responses, whereas mAbs
    that neutralize IL-23 (guselkumab, tildrakizumab and risankizumab) specifically
    block IL-17-secreting cells. The RORγt transcriptional factor is the master regulator
    of IL-17 production in diverse cell types and a target for small molecule drugs
    (SMDs) in development. TH17 cells, γδT17 cells and other IL-17-secreting cells
    (not shown) co-produce IL-17A and IL-17F and, while most of the focus has been
    on mAbs specific for IL-17A (secukinumab and ixekizumab), antibodies that neutralize
    both IL-17A and IL-17F (bimekizumab) are also in clinical use. These, together
    with mAbs that bind to IL-17RA (brodalumab) and inhibit binding of IL-17A and
    IL-17F to IL-17RA–IL-17RC, appear to be marginally more effective than anti-IL-17A
    mAbs. Finally, peptides, macrocycles and other SMDs that target IL-17R or ACT1
    are also in development. GM-CSF, granulocyte–macrophage colony-stimulating factor;
    PAMP, pathogen-associated molecular pattern.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IL18
  - IL17A
  - IL17F
  - CSF2
  - IL21
  - IFNG
  - IL17RA
  - IL17RC
  - ADM
  - YME1L1
  - NECTIN1
  - NR1I2
  - ATP6AP2
  - IL37
  - IL23A
  - IL12A
  - IL12B
  - GPX4
  - IL22
  - NFKB1
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - CXCL10
  - CXCL11
  - CXCL12
  - CXCL13
  - CXCL14
  - CXCL9
  - PF4
  - CXCL1
  - CXCL2
  - CXCL3
  - CXCL5
  - CXCL6
  - CXCL8
  - PPBP
  - Nectin1
  - Atp6ap2
  - Il18
  - Il23a
  - Snrpn
  - Il17a
  - Il17f
  - Csf2
  - Il21
  - Ifng
  - Il17ra
  - Il17rc
  - Nfkb1
---
